CSLT Castlight Health Inc

2

3

This Amendment No. 1 (this “ Amendment No. 1 ”) is filed to report Amendment No. 1 to Warrant, made and entered into as of April 24, 2017, by and among SAP Technologies, Inc. (“ SAP Technologies ”) and Castlight Health, Inc. (the “ Issuer ,” and such amendment, the “ Warrant Amendment ”), to the Warrant held by SAP Technologies with respect to shares of Class B common stock, par value $0.0001 per share of the Issuer (the “ Shares ”). It amends and supplements the statement on Schedule 13D originally filed by SAP Technologies and SAP SE (collectively, with SAP Technologies, the “ Reporting Persons ”) with the Securities and Exchange Commission (“ SEC ”) on May 17, 2016. Except as set forth below, all Items of the Schedule 13D (the “ Schedule 13D ”) remain unchanged.

ITEM 4. PURPOSE OF TRANSACTION

Item 4 of the Schedule 13D is hereby amended by inserting the following at the end of Item 4:

On April 24, 2017, the Issuer and SAP Technologies executed the Warrant Amendment, pursuant to which the Warrant will now expire four years from the date the Issuer and SAP Technologies (or one of its affiliates) enter into a Solution Extension Reseller Agreement (the “ SolEx Agreement ”), a global reseller agreement through the SAP Solution Extension program, whereby SAP Technologies or its affiliates resell a mutually agreed product of the Issuer. If the Issuer and SAP Technologies (or one of its affiliates) do not enter into the SolEx Agreement by November 17, 2017, then the Warrant will become void.

A copy of the Warrant Amendment is filed as Exhibit 2.3 hereto and is incorporated by reference into this Item 4. The description of the Warrant Amendment and the transactions contemplated thereby is qualified in its entirety by reference to the full text of the Warrant Amendment.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Item 5 of Schedule 13D is hereby amended by replacing the third paragraph thereof with the following:

On the Closing Date, SAP Technologies also obtained the right to acquire the Warrant Shares pursuant to the terms of the Warrant. The Warrant Shares represent approximately 3.7% of the currently outstanding Shares. Vesting of the Warrant remains subject to entry by the Issuer and SAP Technologies (or one of its affiliates) into the SolEx Agreement. The Reporting Persons are therefore not currently beneficial owners of the Warrant Shares and hereby disclaim beneficial ownership of the Warrant Shares.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

Item 6 of Schedule 13D is hereby amended by replacing the second paragraph thereof with the following:

Other than the Distribution Agreement entered into between the Issuer and an affiliate of SAP Technologies in August 2016 and an understanding that the Issuer and SAP Technologies (or one of its affiliates) will seek to enter into the SolEx Agreement, and other than the transactions contemplated by the Securities Purchase Agreement and the Warrant as described in Items 4 and 5 above, to the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among each Reporting Person and any other person or entity, including the persons listed in Schedule A hereto, with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

Item 7 is hereby amended by inserting the following at the end of Item 7:

4

5

SIGNATURE

After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned hereby certify as of April 27, 2017 that the information set forth in this statement is true, complete and correct.

6

INDEX OF EXHIBITS

7